BioCentury | Jun 9, 2020
Product Development
Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic
...Editor
Veklury, remdesivir (GS-5734)
Junshi-COVID-19-unknown
AZD1222, ChAdOx1 nCov-19 (ChAdOx1)
Gilead Sciences Inc.
Shanghai Junshi Biosciences Co.
Eli Lilly and Co.
Oxford BioMedica plc
Morningside Venture Partners
AstraZeneca...
